227 Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)

S Weidinger,A Blauvelt,K Papp,A Reich,C.-H Lee,M Worm,C Lynde,Y Kataoka,P Foley,C Weber,W Wong,N Rynkiewicz,K Yen,J.T O’Malley,C Bernigaud

doi:10.1016/j.jid.2023.09.235

227 Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)

S Weidinger, A Blauvelt + Show 13 more

Open Access

PDF Available

https://doi.org/10.1016/j.jid.2023.09.235

Copy DOI

Export

Save

Cite

Journal: Journal of Investigative Dermatology	Publication Date: Nov 1, 2023
Citations: 4

Affiliation: University Hospital Schleswig-Holstein, University of Toronto, University Dermatology, Kaohsiung Chang Gung Memorial Hospital

#Phase 2b Trial #Atopic Dermatitis #anti-OX40 Antibody #Ligand Antibody #Phase 2b

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

227 Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Investigative Dermatology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

227 Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)